Synchromate®

Sodium cloprostenol 0,25 mg/ml

TREATS CYCLE DISORDERS
in cows and mares

INDUCES OR SYNCHRONISES PARTURITION
in cows, sows and mares

REGULATES CORPUS LUTEUM FUNCTION
PGF2α analog

THE MOST POWERFUL LUTEOLYSIS

ALIVIRA
LABORATORIOS KARIZOO S.A.

Benefits of choosing Synchromate®

Sodium cloprostenol 0,25 mg/ml



More powerful

Higher purity of the molecule

Longer half-life

Most active isomer

More resistant to endogenous metabolism

SODIUM CLOPROSTENOL[1,2]

SWINE (sows)

BOVINE (cows)

EQUINE (mares)

Strength	**Cloprostenol 0,25 mg/ml** (0,25 mg of Sodium cloprostenol)		
Indications for use	▪ Induction or synchronization of labor ▪ Complementary treatment for Mastitis Metritis Agalactia Syndrome	▪ Subestrous or silent oestrus ▪ Treatment of luteal cysts ▪ Induction and synchronization of oestrus ▪ Termination of pregnancy ▪ Expulsion of mummified foetus ▪ Induction of parturition ▪ Treatment in chronic endometritis and pyometra	▪ Induction of luteolysis ▪ Treatment of persistent dioestrus ▪ Treatment of pseudo-pregnancy ▪ Treatment of lactation anoestrus ▪ Induction of oestrus ▪ Induction of labour
Administration route	Deep intramuscular injection		
Dosage	Single dose of 0,7 ml/animal	Single dose of 2,0 ml/animal	Single dose of 0,5-2 ml/animal
Withdrawal period	Meat: 2 days	Meat: 2 days Milk: 0 days	Meat: 28 days

Synchromate 0.25 mg/ml solution for injection for cattle, pigs and horses. **Qualitative and quantitative composition** Active substance: Cloprostenol 0.25 mg. (corresponds to Cloprostenol sodium 0.263 mg). Excipients: Qualitative composition of excipients and other constituents. Chlorocresol. Citric acid monohydrate. Ethanol (96 per cent). Sodium chloride. Sodium citrate. Water for injections. Clear colorless solution. **Target species** Cattle (cows), pigs (sows) and horses (mares). **Indications for use, for each target species, Cattle (Cows):** Subestrous or silent oestrus. Treatment of luteal cysts. Induction and synchronization of estrus. Termination of pregnancy until day 150 of pregnancy. Expulsion of mummified foetus. Induction of parturition after 270 days of pregnancy. Adjuvant treatment in chronic endometritis and pyometra. Pigs (Sows): Induction of labor or synchronization of labor from day 114 of pregnancy (the last insemination day counted as the 1st day of pregnancy).Horses (Mares): Induction of luteolysis. Treatment of persistent dioestrus. Treatment of pseudo-pregnancy. Treatment of lactation anestrus. Induction of estrous cycle. Induction of labour after 320 days of pregnancy. **Contraindications** Do not administer to pregnant animals in which induction of abortion or parturition is not desired. Do not administer in case of spastic disease of the respiratory system and gastrointestinal tract and cardiovascular diseases. Do not use to induce abortion in case of dystocia due to mechanical obstruction or abnormal positioning of foetus. Do not use in case of known hypersensitivity to active substance or excipients. Do not administer intravenously. **Special warnings** Avoid induction of too early farrowing in multiparous and primiparous sows. Induction of labour two days prior to the average duration of gestation can lead to an increase in stillbirth of piglets. **Special precautions for safe use in use in the target species:** Induction of parturition and abortion may increase the risk of complications, retained placenta, foetal death and metritis. To reduce the risk of anaerobic infections, which might be related to the pharmacological properties of prostaglandins, care should be taken to avoid injection through contaminated areas of skin. Clean and disinfect injection sites thoroughly before administration. In case of oestrus induction in cows: from the 2nd day after injection, adequate heat detection is necessary. **Special precautions to be taken by the person administering the veterinary medicinal product to animals** Prostaglandins of the F2α type, such as cloprostenol, can be absorbed through the skin and may cause bronchospasm or miscarriage. Care should be taken when handling the product to avoid self-injection or skin contact, especially by pregnant women, women of child-bearing age, asthmatics and people with bronchial or other respiratory problems. Wear disposable impervious gloves when administering the veterinary medicinal product. Direct contact with the skin or eyes may cause irritation and allergic reactions. People with known hypersensitivity to cloprostenol or chlorocresol should avoid contact with the veterinary medicinal product. Accidental spillage on the skin or into the eyes should be washed off immediately with plenty of water. In case of accidental self-injection or spillage on the skin, seek medical advice immediately, particularly as shortness of breath may occur, and show the package leaflet or the label to the physician. Do not eat, drink or smoke while handling the veterinary medicinal product. **Special precautions for the protection of the environment:** Not applicable. **Use during pregnancy, lactation or lay** Do not administer to pregnant animals unless the objective is to terminate the pregnancy. The veterinary medicinal product can be used during lactation. **Interaction with other medicinal products and other forms of interaction** Simultaneous use of oxytocin and Cloprostenol increases the intensity and frequency of uterine contractions.In animals treated with a progestogen, a decreased response to progestogen is to be expected. Do not administer together with Non-steroidal Anti-inflammatory Drugs (NSAID) as they inhibit endogenous prostaglandin synthesis. **Administration routes and dosage** Route of application : deep intramuscular injection. To reduce the risk of anaerobic infection, thoroughly clean and disinfect the injection site before application. Cattle (Cows): 0.5 mg Cloprostenol/animal corresponding to 2.0 ml product / animal. Subestrus or silent heat / oestrus induction : Administer the drug, after determining the presence of the corpus luteum. Heat is generally observed within 2-5 days after treatment. Inseminate at 72-96 hours. Pregnancy interruption : The administration should be carried out between the first week and the day 150 gestation. Abortion occurs after 4-5 days. Endometritis or pyometra : Administer a single dose of the drug. If necessary repeat treatment 10-14 days later. Pigs (Sows): 0.175 mg Cloprostenol/animal corresponding to 0.7 ml of product / animal as a single dose. Induction of labor must be performed within 24-48 hours prior to the expected date of the same to reduce the risk of mortality in piglets. Delivery usually occurs at 19-29 hours of its administration. Horses (Mares): Ponies: single dose of 0.5-1.0 ml (equivalent to 125-250 mcg of cloprostenol) per animal. Thoroughbreds, hunters and heavy horses: single dose of 1-2 ml (equivalent to 250- 500 mcg cloprostenol) per animal. For 20ml vials: "The bromobutyl rubber stoppers may be safely punctured up to 10 times with 16-gauge needle". For 10 ml vials: "Laminated elastomeric bromobutyl rubber stopper may be safely punctured up to 5 times with 16-gauge needle". **Withdrawal period** Cattle (cows): Meat and offal: 2 days. Milk: Zero days. Pig (sows): Meat and offal: 2 days. Horses (mares): Meat and offal: 28 days. **ATCvet code:** QG02AD90. **Major incompatibilities** In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. **Shelf life** Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 28 days. **Nature and composition of immediate packaging** Contents 10 and 20 ml. For 20 ml: Clear glass vials of glass type I with Ph.Eur type I bromobutyl rubberstopper and aluminum cap. For 10 ml: Clear glass vials of glass type I with Ph.Eur type I laminated elastomeric bromobutyl rubber stopper and aluminum cap. Cardboard box containing 1vial of 10ml, Cardboard box containing 5 vials of 10ml. Cardboard box containing 12 vials of 10ml. Cardboard box containing 1 vial of 20ml. Cardboard box containing 5 vials of 20ml. Cardboard box containing 12 vials of 20ml. Not all pack sizes may be marketed. **Name of the marketing authorisation holder** Alivira Animal Health Limited. **Marketing authorisation number(s)** 4106 ESP. **Date of first authorization:** 09/2022. Veterinary medicinal product subject to prescription. Detailed information on this veterinary medicinal product is available in the Union Product Database.

References: 1. Montaser, A.M. *et al.*, 2016 / **2.** Martins, J.P.N.. *et al.*, 2011

900263_01/2023

Laboratorios Karizoo, s.a.
An Alivira Group Company

Polig. Industrial La Borda
Mas Pujades, 11-12
08140 Caldes de Montbui
Barcelona, Spain

T +34 938 654 148
F +34 938 654 648
karizoo@alivira.es
www.alivira.es

ALIVIRA
LABORATORIOS KARIZOO S.A.